Sorafenib News and Research

RSS
Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).
RCC benefit independent of sorafenib, sunitinib sequence order

RCC benefit independent of sorafenib, sunitinib sequence order

Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Study identifies BLU-554 as potential treatment option for HCC patients

Study identifies BLU-554 as potential treatment option for HCC patients

Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

Some lung cancer patients can benefit from melanoma drugs

Some lung cancer patients can benefit from melanoma drugs

Delcath expands global Phase 2 program to treat hepatocellular carcinoma

Delcath expands global Phase 2 program to treat hepatocellular carcinoma

Sunitinib holds promise for treatment of advanced differentiated thyroid cancer

Sunitinib holds promise for treatment of advanced differentiated thyroid cancer

SARAH study completes patient enrolment to evaluate treatment for primary liver cancer

SARAH study completes patient enrolment to evaluate treatment for primary liver cancer

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Two widely used targeted therapy drugs not effective in preventing return of kidney cancer

Two widely used targeted therapy drugs not effective in preventing return of kidney cancer

Study results report no benefit from use of sunitinib, sorafenib among patients with kidney cancer

Study results report no benefit from use of sunitinib, sorafenib among patients with kidney cancer

GenSpera reports encouraging results from mipsagargin Phase II study for HCC treatment

GenSpera reports encouraging results from mipsagargin Phase II study for HCC treatment

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

Novel targeted therapies and treatment combinations for leukemia

Novel targeted therapies and treatment combinations for leukemia

Quality of life maintained during mRCC TKI therapy

Quality of life maintained during mRCC TKI therapy

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

Drug everolimus fails to improve overall survival in advanced liver cancer patients

Drug everolimus fails to improve overall survival in advanced liver cancer patients

Elderly mRCC patients should not be excluded from targeted therapy option

Elderly mRCC patients should not be excluded from targeted therapy option